Укр
Eng
On September 19, 2025, Resolution of the Cabinet of Ministers of Ukraine No. 895 of July 14, 2025 will come into force, introducing substantial amendments to the Licensing Conditions for manufacturers, importers and retailers of medicinal products.
These new provisions require immediate attention, as they impose new transparency obligations, expand the scope of compliance with the 20% quota for product sales, and introduce new rules for pharmacies.
The most significant changes pertain to the practical implementation of Article 20-4 of the Law of Ukraine "On Medicinal Products," which restricts the sale of a finished medicinal product to a single buyer (including related parties) to 20% of the net revenue for the previous year.
1. New obligation: Transparency of cooperation terms.
Manufacturers and importers are now mandated to publicly disclose the terms of sale of their products. This information must be available on the official website or disseminated through other channels of electronic communication (for example, e-mail, messengers).
The disclosure must include:
2. The list of grounds for exceeding the 20% quota has been detailed.
The Regulation shall clarify the circumstances under which a manufacturer or importer may lawfully sell more than 20% of the volume to a single buyer. This is permitted, particularly, if:
Important note: These exceptions do not constitute a blanket exemption. Sales exceeding the 20% of the quota must be conducted on equal terms (price, payment terms and delivery) for all buyers in similar circumstances.
Although the new rules provide more clarity, they do not eliminate all potential risks. The Antimonopoly Committee of Ukraine (AMCU), guided by its Recommendations No. 3-rk on cooperation with distributors, is expected to meticulously analyze the reasons why the manufacturer did not conclude agreements with a sufficient number of distributors. It is important to have a substantiated evidence base for each decision to decline cooperation.
The amendments also address the retail segment:
The revised Licensing Conditions represent a market signal of strengthen oversight concerning transparency and competition.
1. For manufacturers and importers: It is necessary to urgently review and formalize your commercial policies, as well as develop a procedure for their publication. It is important to be ready to justify all refusals to conclude an agreement or all sales exceeding the 20% quota.
2. For pharmacy chains: It is advisable to verify compliance of names and signs with the new requirements, as well as to ensure timely submission of chain affiliation to avoid regulatory sanctions.
The LA Law Firm team stands ready to provide comprehensive support in adapting to the new requirements, including:
Should you have any queries or suggestions, feel free to contact Andrii Gorbatenko, Partner and Head of Antitrust and Competition at LA Law Firm, via gorbatenko@l-a.com.ua.
We are thrilled to announce a major milestone in our team's growth and celebrate the well-deserved career advancements of our colleagues.
Lexology Index: Employment & Labor highlights the leading legal specialists in the field from around the world.
On June 19, 2026, an event was held with the participation of businesses, regulators, and experts – titled “Regulatory Dialogue: The Cosmetics Market” – organiz
The event brought together leading industry experts for a comprehensive analysis of the institutional landscape and current legal challenges in the sphere of state-business interaction.
